TABLE 2.
Baseline and 12-wk body composition outcomes in women with ovarian or endometrial cancer who consumed the ACS and KD1
| ACS (n = 20) | KD (n = 25) | |||
|---|---|---|---|---|
| Week 0 | Week 12 | Week 0 | Week 12 | |
| Total fat mass, kg | 44.1 ± 4.6 | 41.2 ± 4.4 | 37.9 ± 3.2 | 32.7 ± 3.1* |
| Android fat, kg | 3.9 ± 0.5 | 3.6 ± 0.5 | 3.4 ± 0.4 | 2.8 ± 0.4* |
| Visceral fat,2 g | 1150 ± 210.0 | 1024 ± 175.6 | 1152 ± 164.6 | 975 ± 150.9* |
| Trunk fat, kg | 22.2 ± 2.6 | 20.9 ± 2.4 | 19.4 ± 1.8 | 16.3 ± 1.8*** |
| Gynoid fat, kg | 7.7 ± 0.9 | 7.3 ± 0.8 | 6.6 ± 0.5 | 5.7 ± .05*** |
| Arm fat, kg | 4.8 ± 0.5 | 4.6 ± 0.5 | 4.2 ± 0.4 | 3.7 ± 0.4* |
| Leg fat, kg | 15.5 ± 1.7 | 15.0 ± 1.6 | 13.4 ± 1.1 | 11.8 ± 1.1** |
| Total lean mass, kg | 44.9 ± 2.5 | 44.8 ± 2.8 | 43.3 ± 1.3 | 42.4 ± 1.4 |
1
Values are means ± SEMS. *P < 0.05; **P < 0.01; ***P < 0.001 compared with week 12 ACS. P values from ANCOVA, adjusted for baseline condition. ACS, American Cancer Society diet; KD, ketogenic diet.
2
Visceral fat mass data were not available for 5 participants.